The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

@article{Park2010TheTE,
  title={The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.},
  author={SaeGwang Park and Zhujun Jiang and Eric D. Mortenson and Liufu Deng and Olga Radkevich-Brown and Xuanming Yang and Husain A. Sattar and Yibing Wang and Nicholas K. Brown and Mark Greene and Yang Liu and Jie Tang and Shengdian Wang and Yang-Xin Fu},
  journal={Cancer cell},
  year={2010},
  volume={18 2},
  pages={
          160-70
        }
}
Anti-HER2/neu antibody therapy is reported to mediate tumor regression by interrupting oncogenic signals and/or inducing FcR-mediated cytotoxicity. Here, we demonstrate that the mechanisms of tumor regression by this therapy also require the adaptive immune response. Activation of innate immunity and T cells, initiated by antibody treatment, was necessary. Intriguingly, the addition of chemotherapeutic drugs, although capable of enhancing the reduction of tumor burden, could abrogate antibody… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 185 CITATIONS, ESTIMATED 63% COVERAGE

Immunotherapy against HER2-positive breast cancers /

VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2017
VIEW 14 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2010
2019

CITATION STATISTICS

  • 16 Highly Influenced Citations

  • Averaged 18 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 46 REFERENCES

Chemotherapy: friend or foe to cancer vaccines?

  • Current opinion in molecular therapeutics
  • 2001
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2008
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Trastuzumab--mechanism of action and use in clinical practice.

  • The New England journal of medicine
  • 2007
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2006
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL